Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jefferies hikes price target on DCC, says 'simplicity can unlock value'

(Sharecast News) - Jefferies hiked its price target on buy-rated DCC on Tuesday after the sales, marketing and support services group announced last week that it was planning to simplify its operations and focus on the energy sector. The price target was lifted to 7,950p from 7,600p.

DCC said last week that it had begun preparations for the sale of DCC Healthcare, which is expected to complete next year. In addition, the company will review strategic options for DCC Technology within the next 24 months.

Jefferies said its sum-of-the-parts valuation suggests more than 40% upside potential to the current share price, and, following discussion with management, it is "increasingly confident that the move to simplify the group will unlock embedded value".

"We believe that the misunderstood and underappreciated energy division now commands attention," it said.

Jefferies noted that Health and Tech added two layers of complexity to DCC and more recently have been a drag on growth and returns.

As a pure play on energy distribution, it believes the company will be able to deliver mid single digit organic EBITA growth and mid-teen post-tax return on invested capital.

At 1330 GMT, the shares were up 2% at 5,700p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.